Study of YH42946 for advanced cancer with HER2 or EGFR changes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (YH42946) in people with advanced solid tumors that have specific changes in HER2 or EGFR genes and have stopped responding to standard therapies. The drug aims to target these genetic changes to slow or shrink the cancer. Participants will be monitored closely for safety and how well the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic cancer that has progressed after standard treatments, or where standard treatment is not appropriate.
- Your tumor must have a specific HER2 alteration or EGFR mutation (confirmed by a tumor sample).
- You must be in good physical condition (able to carry out daily activities).
- Your liver, kidney, and bone marrow function must be adequate.
- If you have brain metastases, they must have been treated and be stable.
- You must not have untreated or progressing brain metastases, or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
This trial tests an experimental drug called SYH2095 in people with advanced cancer, particularly a type of breast cancer called HR+/HER2- . The drug is an oral medication that may block certain proteins in cancer cells to slow or stop their growth. If you qualify, you would receive the drug to see how well it works and how safe it is.
This trial tests a new drug called HSK46256 for people with advanced solid tumors that have not responded to standard treatments. The drug may target cancer cells with certain genetic changes, and the study aims to find the best dose and see how well it works.
This trial tests a new drug called YL-17231 in people with advanced solid tumors that have specific changes (mutations) in the KRAS, HRAS, or NRAS genes. It is for patients whose cancer has stopped responding to or cannot tolerate standard treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.